Ein Programm von Bundesärztekammer, Kassenärztlicher Bundesvereinigung und Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften
NVL Hypertonie (2023)

Literaturverzeichnis

  • Abalos E, Duley L, Steyn DW, et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2018; 10(10):CD002252. DOI: 10.1002/14651858.CD002252.pub4. http://www.ncbi.nlm.nih.gov/pubmed/30277556.
  • Acin MT, Rueda J-R, Saiz LC, et al. Alcohol intake reduction for controlling hypertension. Cochrane Database Syst Rev 2020(9):CD010022. DOI: 10.1002/14651858.CD010022.pub2. http://www.ncbi.nlm.nih.gov/pubmed/32960976.
  • Adler AJ, Taylor F, Martin N, et al. Reduced dietary salt for the prevention of cardiovascular disease. Cochrane Database Syst Rev 2014(12):CD009217. DOI: 10.1002/14651858.CD009217.pub3. http://www.ncbi.nlm.nih.gov/pubmed/25519688.
  • Agency for Healthcare Research and Quality (AHRQ). Screening for High Blood Pressure in Adults: A Systematic Evidence Review for the U.S. Preventive Services Task Force. 2014 (Evidence Synthesis; 121) [cited: 2020-01-14]. https://www.ncbi.nlm.nih.gov/books/NBK269495/pdf/Bookshelf_NBK269495.pdf.
  • Ågesen FN, Weeke PE, Tfelt-Hansen P, et al. Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology. Pharmacol Res Perspect 2019; 7(4):e00496. DOI: 10.1002/prp2.496. http://www.ncbi.nlm.nih.gov/pubmed/31338197.
  • Ah Y-M, Shin J, Lee J-Y. The association of angiotensin receptor blocker-based combination therapy with persistence and adherence in newly treated, uncomplicated hypertensive patients. Patient Prefer Adherence 2019; 13:241–8. DOI: 10.2147/PPA.S195423. http://www.ncbi.nlm.nih.gov/pubmed/30774320.
  • Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Das AWMF-Regelwerk Leitlinien. München: Zuckschwerdt; 2012.
  • Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)-Ständige Kommission Leitlinien. AWMF-Regelwerk Leitlinien: Version 2.0. 2020 [cited: 2021-03-22]. http://www.awmf.org/leitlinien/awmf-regelwerk.html.
  • Arguedas JA, Leiva V, Wright JM. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database Syst Rev 2013(10):CD008277. DOI: 10.1002/14651858.CD008277.pub2. http://www.ncbi.nlm.nih.gov/pubmed/24170669.
  • Arguedas JA, Leiva V, Wright JM. Blood pressure targets in adults with hypertension. Cochrane Database Syst Rev 2020; 12(12):CD004349. DOI: 10.1002/14651858.CD004349.pub3. http://www.ncbi.nlm.nih.gov/pubmed/33332584.
  • Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev 2009(3):CD004349. http://www.ncbi.nlm.nih.gov/pubmed/19588353.
  • Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328(7454):1490–7. http://www.ncbi.nlm.nih.gov/pubmed/15205295.
  • Azizi M, Daemen J, Lobo MD, et al. 12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. JACC Cardiovasc Interv 2020; 13(24):2922–33. DOI: 10.1016/j.jcin.2020.09.054. http://www.ncbi.nlm.nih.gov/pubmed/33357531.
  • Azizi M, Sanghvi K, Saxena M, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): A randomised, multicentre, single-blind, sham-controlled trial. Lancet 2021; 397(10293):2476–86. DOI: 10.1016/S0140-6736(21)00788-1. http://www.ncbi.nlm.nih.gov/pubmed/34010611.
  • Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): A multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 2018; 391(10137):2335–45. DOI: 10.1016/S0140-6736(18)31082-1. http://www.ncbi.nlm.nih.gov/pubmed/29803590.
  • Azizi M, Schmieder RE, Mahfoud F, et al. Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. Circulation 2019:[Epub ahead of print]. DOI: 10.1161/CIRCULATIONAHA.119.040451. http://www.ncbi.nlm.nih.gov/pubmed/30880441.
  • Bakris GL, Townsend RR, Flack JM, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: The SYMPLICITY HTN-3 trial. J Am Coll Cardiol 2015; 65(13):1314–21. DOI: 10.1016/j.jacc.2015.01.037. http://www.ncbi.nlm.nih.gov/pubmed/25835443.
  • Bakris GL, Townsend RR, Liu M, et al. Impact of renal denervation on 24-hour ambulatory blood pressure: Results from SYMPLICITY HTN-3. J Am Coll Cardiol 2014; 64(11):1071–8. DOI: 10.1016/j.jacc.2014.05.012. http://www.ncbi.nlm.nih.gov/pubmed/24858423.
  • Barra M de, Scott CL, Scott NW, et al. Pharmacist services for non-hospitalised patients. Cochrane Database Syst Rev 2018; 9(9):CD013102. DOI: 10.1002/14651858.CD013102. http://www.ncbi.nlm.nih.gov/pubmed/30178872.
  • Batterink J, Stabler SN, Tejani AM, et al. Spironolactone for hypertension. Cochrane Database Syst Rev 2010(8):CD008169. DOI: 10.1002/14651858.CD008169.pub2. http://www.ncbi.nlm.nih.gov/pubmed/20687095.
  • Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370(15):1393–401. DOI: 10.1056/NEJMoa1402670. http://www.ncbi.nlm.nih.gov/pubmed/24678939.
  • Bieber C, Gschwendtner K, Müller N, et al. Partizipative Entscheidungsfindung (PEF) - Patient und Arzt als Team. Psychother Psychosom Med Psychol 2016; 66(5):195–207. DOI: 10.1055/s-0042-105277. http://www.ncbi.nlm.nih.gov/pubmed/27119359.
  • Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: Results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011; 58(7):765–73. DOI: 10.1016/j.jacc.2011.06.008. http://www.ncbi.nlm.nih.gov/pubmed/21816315.
  • Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): A multicentre, randomised, sham-controlled trial. Lancet 2020; 395(10234):1444–51. DOI: 10.1016/S0140-6736(20)30554-7. http://www.ncbi.nlm.nih.gov/pubmed/32234534.
  • Böhm M, Mahfoud F, Ukena C, et al. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension 2015; 65(4):766–74. DOI: 10.1161/HYPERTENSIONAHA.114.05010. http://www.ncbi.nlm.nih.gov/pubmed/25691618.
  • Breitscheidel L, Ehlken B, Kostev K, et al. Real-life treatment patterns, compliance, persistence, and medication costs in patients with hypertension in Germany. J Med Econ 2012; 15(1):155–65. DOI: 10.3111/13696998.2011.635229. http://www.ncbi.nlm.nih.gov/pubmed/22035215.
  • Bundesärztekammer (BÄK). Gemeinsame Stellungnahme der Bundesärztekammer und der Arzneimittelkommission der deutschen Ärzteschaft: zum Entwurf eines Gesetzes zur Stärkung der Vor-Ort-Apotheken (BT-Drs. 19/21732) und zum Antrag der Fraktion der FDP "Versorgungssicherheit mit Arzneimitteln gewährleisten – Produktion in Europa stärken" (BT-Drs. 19/18931). 2020 [cited: 2023-06-20]. https://www.bundesaerztekammer.de/fileadmin/user_upload/_old-files/downloads/pdf-Ordner/Stellungnahmen/Vor-Ort-Apotheken-Gesetz_SN_BAEK_AkdAE_09092020_final.pdf.
  • Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Programm für Nationale VersorgungsLeitlinien - Methodenreport, 5. Auflage. Version 1. 2017 [cited: 2019-09-05]. DOI: 10.6101/AZQ/000169. http://doi.org/10.6101/AZQ/000169.
  • Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Hypertonie – Leitlinienreport. Version 1.0. 2023 [cited: 2023-06-20]. DOI: 10.6101/AZQ/000501. http://doi.org/10.6101/AZQ/000501.
  • Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV). Beurteilungskriterien für Leitlinien in der medizinischen Versorgung - Beschlüsse der Vorstände der Bundesärztekammer und Kassenärztlicher Bundesvereinigung, Juni 1997. Dtsch Arztebl 1997; 94(33):A-2154-5.
  • Bundesministerium für Gesundheit und soziale Sicherung (BMGS). Neuntes Buch Sozialgesetzbuch vom 23. Dezember 2016 (BGBl. I S. 3234): Zuletzt geändert durch Art. 7c des Gesetzes vom 27. September 2021 (BGBl. I S. 4530). 2016 [cited: 2022-07-04]. https://www.gesetze-im-internet.de/sgb_9_2018/index.html.
  • Calderon A, Barrios V, Escobar C, et al. Detection of left ventricular hypertrophy by different electrocardiographic criteria in clinical practice. Findings from the Sara study. Clin Exp Hypertens 2010; 32(3):145–53. DOI: 10.3109/10641960903254455. http://www.ncbi.nlm.nih.gov/pubmed/20504121.
  • Cao L, Li X, Yan P, et al. The effectiveness of aerobic exercise for hypertensive population: A systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2019; 21(7):868–76. DOI: 10.1111/jch.13583. http://www.ncbi.nlm.nih.gov/pubmed/31169988.
  • Carpenter M, Berry H, Pelletier AL. Clinically Relevant Drug-Drug Interactions in Primary Care. Am Fam Physician 2019; 99(9):558–64. http://www.ncbi.nlm.nih.gov/pubmed/31038898.
  • Chen N, Zhou M, Yang M, et al. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database Syst Rev 2010(8):CD003654. DOI: 10.1002/14651858.CD003654.pub4. http://www.ncbi.nlm.nih.gov/pubmed/20687074.
  • Chen YJ, Li LJ, Tang WL, et al. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev 2018; 11(11):CD008170. DOI: 10.1002/14651858.CD008170.pub3. http://www.ncbi.nlm.nih.gov/pubmed/30480768.
  • Costa EC, Hay JL, Kehler DS, et al. Effects of High-Intensity Interval Training Versus Moderate-Intensity Continuous Training On Blood Pressure in Adults with Pre- to Established Hypertension: A Systematic Review and Meta-Analysis of Randomized Trials. Sports Med 2018; 48(9):2127–42. DOI: 10.1007/s40279-018-0944-y. http://www.ncbi.nlm.nih.gov/pubmed/29949110.
  • Desch S, Okon T, Heinemann D, et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension 2015; 65(6):1202–8. DOI: 10.1161/HYPERTENSIONAHA.115.05283. http://www.ncbi.nlm.nih.gov/pubmed/25824248.
  • Deutsches Netzwerk Evidenzbasierte Medizin (DNEbM). Gute Praxis Gesundheitsinformation. Ein Positionspapier des Deutschen Netzwerks Evidenzbasierte Medizin. Version 2.0. Stand: 18.10.2015. 2015 [cited: 2017-10-17]. http://www.ebm-netzwerk.de/pdf/publikationen/gpgi2.pdf.
  • Deutsches Netzwerk Evidenzbasierte Medizin (DNEbM). Gute Praxis Gesundheitsinformation. Liste der Unterzeichner. 2016 [cited: 2018-02-07]. http://www.ebm-netzwerk.de/pdf/publikationen/gpgi-unterzeichner.pdf.
  • Devi R, Singh SJ, Powell J, et al. Internet-based interventions for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2015(12):CD009386. DOI: 10.1002/14651858.CD009386.pub2. http://www.ncbi.nlm.nih.gov/pubmed/26691216.
  • Dhalla IA, Gomes T, Yao Z, et al. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: A population-based cohort study. Ann Intern Med 2013; 158(6):447–55. DOI: 10.7326/0003-4819-158-6-201303190-00004. http://www.ncbi.nlm.nih.gov/pubmed/23552325.
  • Di Zhao, Liu H, Dong P. Chronotherapy of Hypertension with Angiotensin Receptor Blockers-A Meta-Analysis of Blood Pressure Measured by Ambulatory Blood Pressure Monitoring in Randomized Trials. Am J Med Sci 2021; 361(1):36–42. DOI: 10.1016/j.amjms.2020.07.031. http://www.ncbi.nlm.nih.gov/pubmed/32948291.
  • Dineva S, Uzunova K, Pavlova V, et al. Comparative efficacy and safety of chlorthalidone and hydrochlorothiazide-meta-analysis. J Hum Hypertens 2019; 33(11):766–74. DOI: 10.1038/s41371-019-0255-2. http://www.ncbi.nlm.nih.gov/pubmed/31595024.
  • Dorsch MP, Gillespie BW, Erickson SR, et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: A retrospective cohort analysis. Hypertension 2011; 57(4):689–94. DOI: 10.1161/HYPERTENSIONAHA.110.161505. http://www.ncbi.nlm.nih.gov/pubmed/21383313.
  • Ernst ME, Neaton JD, Grimm RH, et al. Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. Hypertension 2011; 58(6):1001–7. DOI: 10.1161/HYPERTENSIONAHA.111.181248. http://www.ncbi.nlm.nih.gov/pubmed/22025372.
  • Eschmann E, Beeler PE, Schneemann M, et al. Developing strategies for predicting hyperkalemia in potassium-increasing drug-drug interactions. J Am Med Inform Assoc 2017; 24(1):60–6. DOI: 10.1093/jamia/ocw050. http://www.ncbi.nlm.nih.gov/pubmed/27174894.
  • Europarat, Verbindung der Schweizer Ärztinnen und Ärzte, Ärztliche Zentralstelle Qualitätssicherung (ÄZQ), et al. Entwicklung einer Methodik für die Ausarbeitung von Leitlinien für optimale medizinische Praxis. Empfehlung Rec (2001)13 des Europarates am 10. Oktober 2001 und Erläuterndes Memorandum. Deutschsprachige Ausgabe. Z Arztl. Fortbild. Qualitatssich. 2002; 96(Suppl III):3–60.
  • Fengler K, Rommel K-P, Blazek S, et al. A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUND-HTN). Circulation 2019; 139(5):590–600. DOI: 10.1161/CIRCULATIONAHA.118.037654. http://www.ncbi.nlm.nih.gov/pubmed/30586691.
  • Finger JD, Mensink GBM, Lange C. Arbeitsbezogene körperliche Aktivität bei Erwachsenen in Deutschland. J Health Monit 2017; 2(2):29–36. DOI: 10.17886/RKI-GBE-2017-026.
  • Finger JD, Mensink GBM, Lange C. Gesundheitsfördernde körperliche Aktivität in der Freizeit bei Erwachsenen in Deutschland. J Health Monit 2017; 2(2):37–44. DOI: 10.17886/RKI-GBE-2017-027.
  • Flodgren G, Rachas A, Farmer AJ, et al. Interactive telemedicine: Effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2015; 9:CD002098. DOI: 10.1002/14651858.CD002098.pub2. http://www.ncbi.nlm.nih.gov/pubmed/26343551.
  • Fravel MA, Ernst M. Drug Interactions with Antihypertensives. Curr Hypertens Rep 2021; 23(3):14. DOI: 10.1007/s11906-021-01131-y. http://www.ncbi.nlm.nih.gov/pubmed/33666764.
  • Garjón J, Saiz LC, Azparren A, et al. First-line combination therapy versus first-line monotherapy for primary hypertension. Cochrane Database Syst Rev 2020; 2(2):CD010316. DOI: 10.1002/14651858.CD010316.pub3. http://www.ncbi.nlm.nih.gov/pubmed/32026465.
  • Garrison SR, Kolber MR, Korownyk CS, et al. Blood pressure targets for hypertension in older adults. Cochrane Database Syst Rev 2017; 8(8):CD011575. DOI: 10.1002/14651858.CD011575.pub2. http://www.ncbi.nlm.nih.gov/pubmed/28787537.
  • GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396(10258):1223–49. DOI: 10.1016/S0140-6736(20)30752-2. http://www.ncbi.nlm.nih.gov/pubmed/33069327.
  • Ghamami N, Chiang SH, Dormuth C, et al. Time course for blood pressure lowering of dihydropyridine calcium channel blockers. Cochrane Database Syst Rev 2014(8):CD010052. DOI: 10.1002/14651858.CD010052.pub2. http://www.ncbi.nlm.nih.gov/pubmed/25173808.
  • Glynn LG, Murphy AW, Smith SM, et al. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev 2010(3):CD005182. DOI: 10.1002/14651858.CD005182.pub4. http://www.ncbi.nlm.nih.gov/pubmed/20238338.
  • Gosse P, Jan E, Coulon P, et al. ECG detection of left ventricular hypertrophy: The simpler, the better? J Hypertens 2012; 30(5):990–6. DOI: 10.1097/HJH.0b013e3283524961. http://www.ncbi.nlm.nih.gov/pubmed/22441347.
  • Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride. Cochrane Database Syst Rev 2017; 4(4):CD004022. DOI: 10.1002/14651858.CD004022.pub4. http://www.ncbi.nlm.nih.gov/pubmed/28391629.
  • Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride. Cochrane Database Syst Rev 2020; 12(12):CD004022. DOI: 10.1002/14651858.CD004022.pub5. http://www.ncbi.nlm.nih.gov/pubmed/33314019.
  • Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336(7650):924–6. http://www.ncbi.nlm.nih.gov/pubmed/18436948.
  • Hallan SI, Matsushita K, Sang Y, et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA 2012; 308(22):2349–60. DOI: 10.1001/jama.2012.16817. http://www.ncbi.nlm.nih.gov/pubmed/23111824.
  • Hartley L, Dyakova M, Holmes J, et al. Yoga for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2014(5):CD010072. DOI: 10.1002/14651858.CD010072.pub2. http://www.ncbi.nlm.nih.gov/pubmed/24825181.
  • Hartley L, Flowers N, Lee MS, et al. Tai chi for primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2014(4):CD010366. DOI: 10.1002/14651858.CD010366.pub2. http://www.ncbi.nlm.nih.gov/pubmed/24715694.
  • Hartley L, Lee MS, Kwong JS, et al. Qigong for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2015(6):CD010390. DOI: 10.1002/14651858.CD010390.pub2. http://www.ncbi.nlm.nih.gov/pubmed/26068956.
  • He FJ, Li J, MacGregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev 2013(4):CD004937. DOI: 10.1002/14651858.CD004937.pub2. http://www.ncbi.nlm.nih.gov/pubmed/23633321.
  • Heran BS, Chen JM, Wang JJ, et al. Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension. Cochrane Database Syst Rev 2012; 11(11):CD008167. DOI: 10.1002/14651858.CD008167.pub3. http://www.ncbi.nlm.nih.gov/pubmed/23152254.
  • Heran BS, Galm BP, Wright JM. Blood pressure lowering efficacy of alpha blockers for primary hypertension. Cochrane Database Syst Rev 2012(8):CD004643. DOI: 10.1002/14651858.CD004643.pub3. http://www.ncbi.nlm.nih.gov/pubmed/22895943.
  • Heran BS, Wong MM, Heran IK, et al. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev 2008(4):CD003823. DOI: 10.1002/14651858.CD003823.pub2. http://www.ncbi.nlm.nih.gov/pubmed/18843651.
  • Heran BS, Wong MM, Heran IK, et al. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev 2008(4):CD003822. DOI: 10.1002/14651858.CD003822.pub2. http://www.ncbi.nlm.nih.gov/pubmed/18843650.
  • Hermida RC, Ayala DE, Mojón A, et al. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol 2011; 22(12):2313–21. DOI: 10.1681/ASN.2011040361. http://www.ncbi.nlm.nih.gov/pubmed/22025630.
  • Hermida RC, Ayala DE, Mojón A, et al. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J Am Coll Cardiol 2011; 58(11):1165–73. DOI: 10.1016/j.jacc.2011.04.043. http://www.ncbi.nlm.nih.gov/pubmed/21884956.
  • Hermida RC, Ayala DE, Mojón A, et al. Influence of circadian time of hypertension treatment on cardiovascular risk: Results of the MAPEC study. Chronobiol Int 2010; 27(8):1629–51. DOI: 10.3109/07420528.2010.510230. http://www.ncbi.nlm.nih.gov/pubmed/20854139.
  • Hermida RC, Ayala DE, Smolensky MH, et al. Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks. Hypertens Res 2016; 39(5):277–92. DOI: 10.1038/hr.2015.142. http://www.ncbi.nlm.nih.gov/pubmed/26657008.
  • Hermida RC, Crespo JJ, Domínguez-Sardiña M, et al. Bedtime hypertension treatment improves cardiovascular risk reduction: The Hygia Chronotherapy Trial. Eur Heart J 2020; 41(48):4565–76. DOI: 10.1093/eurheartj/ehz754. http://www.ncbi.nlm.nih.gov/pubmed/31641769.
  • Hermida RC, Ríos MT, Crespo JJ, et al. Treatment-time regimen of hypertension medications significantly affects ambulatory blood pressure and clinical characteristics of patients with resistant hypertension. Chronobiol Int 2013; 30(1-2):192–206. DOI: 10.3109/07420528.2012.701460. http://www.ncbi.nlm.nih.gov/pubmed/23098160.
  • Hermida RC. Sleep-time ambulatory blood pressure as a prognostic marker of vascular and other risks and therapeutic target for prevention by hypertension chronotherapy: Rationale and design of the Hygia Project. Chronobiol Int 2016; 33(7):906–36. DOI: 10.1080/07420528.2016.1181078. http://www.ncbi.nlm.nih.gov/pubmed/27221952.
  • Ho C-T, Tung Y-C, Chou S-H, et al. Clinical outcomes in hypertensive patients treated with a single-pill fixed-dose combination of renin-angiotensin system inhibitor and thiazide diuretic. J Clin Hypertens (Greenwich) 2018; 20(12):1731–8. DOI: 10.1111/jch.13413. http://www.ncbi.nlm.nih.gov/pubmed/30375168.
  • Holstiege J, Akmatov MK, Steffen A, et al. Diagnoseprävalenz der Hypertonie in der vertragsärztlichen Versorgung – aktuelle deutschlandweite Kennzahlen. 2020 (Versorgungsatlas-Bericht; Nr. 20/01) [cited: 2020-03-26]. DOI: 10.20364/VA-20.01. https://www.versorgungsatlas.de/fileadmin/ziva_docs/107/VA_20-01_Bericht_Hypertonie_2020-03-03_1.pdf.
  • Hripcsak G, Suchard MA, Shea S, et al. Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension. JAMA Intern Med 2020; 180(4):542–51. DOI: 10.1001/jamainternmed.2019.7454. http://www.ncbi.nlm.nih.gov/pubmed/32065600.
  • Hsu C-I, Hsiao F-Y, Wu F-LL, et al. Adherence and medication utilisation patterns of fixed-dose and free combination of angiotensin receptor blocker/thiazide diuretics among newly diagnosed hypertensive patients: A population-based cohort study. Int J Clin Pract 2015; 69(7):729–37. DOI: 10.1111/ijcp.12591. http://www.ncbi.nlm.nih.gov/pubmed/25395349.
  • Igarashi Y, Nogami Y. Running to Lower Resting Blood Pressure: A Systematic Review and Meta-analysis. Sports Med 2020; 50(3):531–41. DOI: 10.1007/s40279-019-01209-3. http://www.ncbi.nlm.nih.gov/pubmed/31677122.
  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nutzenbewertung nichtmedikamentöser Behandlungsstrategien bei Patienten mit essenzieller Hypertonie: Steigerung der körperlichen Aktivität. Rapid Report. Auftrag A05/21D. Version 1.0. 2010 (IQWiG-Berichte; 75) [cited: 2019-10-23]. https://iqwig.de/download/A05-21D_Rapid-Report_Nichtmedikamentoese_Behandlungsstrategien_bei_Hypertonie_Steigerung_der_koerperlichen_Aktivitaet.pdf.
  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nutzenbewertung nichtmedikamentöser Behandlungsstrategien bei Patienten mit essenzieller Hypertonie: Spezielle Ernährungsformen ohne primär körpergewichts- oder kochsalzreduzierte Intention. Rapid Report. Auftrag A05/021C. Version 1.0. 2011 (IQWiG-Berichte; 93) [cited: 2019-10-23]. https://iqwig.de/download/A05-21C_RR_Spezielle_Ernaehrungsformen_bei_Hypertonie.pdf.
  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nutzenbewertung nichtmedikamentöser Behandlungsstrategien bei Patienten mit essenzieller Hypertonie: Rauchverzicht. Rapid Report. Auftrag A05-21G. Version 1.0. 2011 (IQWiG-Berichte; 97) [cited: 2019-10-23]. https://iqwig.de/download/A05-21G-Rapid-Report_Nichtmedikamentoese_Behandlungsstrategien_bei_Hypertonie_Rauchverzicht.pdf.
  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nutzenbewertung nichtmedikamentöser Behandlungsstrategien bei Patienten mit essenzieller Hypertonie: Reduktion des Alkoholkonsums. Rapid Report. Auftrag A05-21E. Version 1.0. 2011 (IQWiG-Berichte; 91) [cited: 2019-10-23]. https://iqwig.de/download/A05-21E_Rapid_Report_Reduktion_des_Alkoholkonsums_bei_Hypertonie.pdf.
  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nutzenbewertung nichtmedikamentöser Behandlungsstrategien bei Patienten mit essenzieller Hypertonie: Stressbewältigung. Rapid Report. Auftrag A05-21F. Version 1.0. 2011 (IQWiG-Berichte; 92) [cited: 2019-10-23]. https://iqwig.de/download/A05-21F_Rapid-Report_Nichtmedikamentoese_Behandlungsstrategien_bei_Hypertonie_Stressbewaeltigung_neu.pdf.
  • Ishani A, Cushman WC, Leatherman SM, et al. Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. N Engl J Med 2022; 387(26):2401–10. DOI: 10.1056/NEJMoa2212270. http://www.ncbi.nlm.nih.gov/pubmed/36516076.
  • Jiang X, Quan X, Yang J, et al. Electrocardiographic criteria for the diagnosis of abnormal hypertensive cardiac phenotypes. J Clin Hypertens (Greenwich) 2019; 21(3):372–8. DOI: 10.1111/jch.13486. http://www.ncbi.nlm.nih.gov/pubmed/30706989.
  • Jongh de T, Gurol-Urganci I, Vodopivec-Jamsek V, et al. Mobile phone messaging for facilitating self-management of long-term illnesses. Cochrane Database Syst Rev 2012; 12:CD007459. DOI: 10.1002/14651858.CD007459.pub2. http://www.ncbi.nlm.nih.gov/pubmed/23235644.
  • Kandler MR, Mah GT, Tejani AM, et al. Hydralazine for essential hypertension. Cochrane Database Syst Rev 2011(11):CD004934. DOI: 10.1002/14651858.CD004934.pub4. http://www.ncbi.nlm.nih.gov/pubmed/22071816.
  • Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 2018; 391(10137):2346–55. DOI: 10.1016/S0140-6736(18)30951-6. http://www.ncbi.nlm.nih.gov/pubmed/29803589.
  • Kario K, Yokoi Y, Okamura K, et al. Catheter-based ultrasound renal denervation in patients with resistant hypertension: The randomized, controlled REQUIRE trial. Hypertens Res 2022; 45(2):221–31. DOI: 10.1038/s41440-021-00754-7. http://www.ncbi.nlm.nih.gov/pubmed/34654905.
  • Kassenärztliche Bundesvereinigung (KBV). Medikationskatalog 2021. Hypertonie: Version 1.0. 2021 [cited: 2021-05-11]. https://www.kbv.de/tools/protecteddownloads/deliver.php?s=download&id=fe4b7bda171687bbbac85e228d4c6993.
  • Kaur G, Phillips CL, Wong K, et al. Timing of Administration: For Commonly-Prescribed Medicines in Australia. Pharmaceutics 2016; 8(2). DOI: 10.3390/pharmaceutics8020013. http://www.ncbi.nlm.nih.gov/pubmed/27092523.
  • Kelly DM, Rothwell PM. Proteinuria as an independent predictor of stroke: Systematic review and meta-analysis. Int J Stroke 2020; 15(1):29–38. DOI: 10.1177/1747493019895206. http://www.ncbi.nlm.nih.gov/pubmed/31935154.
  • Klenow S, Mensink GBM. Natriumzufuhr in Deutschland. J Health Monit 2016; 1(2):31–5. DOI: 10.17886/RKI-GBE-2016-035.
  • Köberlein-Neu J, Mennemann H, Hamacher S, et al. Interprofessional Medication Management in Patients With Multiple Morbidities. Dtsch Arztebl Int 2016; 113(44):741–8. DOI: 10.3238/arztebl.2016.0741. http://www.ncbi.nlm.nih.gov/pubmed/27890050.
  • Koopmans AB, Braakman MH, Vinkers DJ, et al. Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19. Transl Psychiatry 2021; 11(1):141. DOI: 10.1038/s41398-020-01129-1. http://www.ncbi.nlm.nih.gov/pubmed/33627619.
  • Kuhl JT, Nielsen JB, Stisen ZR, et al. Left ventricular hypertrophy identified by cardiac computed tomography and ECG in hypertensive individuals: A population-based study. J Hypertens 2019; 37(4):739–46. DOI: 10.1097/HJH.0000000000001962. http://www.ncbi.nlm.nih.gov/pubmed/30817455.
  • Kumar B, Kaur S, Manzoor S, et al. First among equals: A comparative study of the effect of hydrochlorothiazide and chlorthalidone on recently diagnosed hypertensives. Asian journal of pharmaceutical and clinical research 2015; 8(6):195–8. https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01126131/full.
  • Lange C, Manz K, Kuntz RE. Alkoholkonsum bei Erwachsenen in Deutschland: Riskante Trinkmengen. J Health Monit 2017; 2(2):66–73. DOI: 10.17886/RKI-GBE-2017-031.
  • Laurant M, van der Biezen M, Wijers N, et al. Nurses as substitutes for doctors in primary care. Cochrane Database Syst Rev 2018; 7(7):CD001271. DOI: 10.1002/14651858.CD001271.pub3. http://www.ncbi.nlm.nih.gov/pubmed/30011347.
  • Lee L-L, Mulvaney CA, Wong YK, et al. Walking for hypertension. Cochrane Database Syst Rev 2021; 2(2):CD008823. DOI: 10.1002/14651858.CD008823.pub2. http://www.ncbi.nlm.nih.gov/pubmed/33630309.
  • Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev 2014(8):CD009096. DOI: 10.1002/14651858.CD009096.pub2. http://www.ncbi.nlm.nih.gov/pubmed/25148386.
  • Liang W, Ma H, Cao L, et al. Comparison of thiazide-like diuretics versus thiazide-type diuretics: A meta-analysis. J Cell Mol Med 2017; 21(11):2634–42. DOI: 10.1111/jcmm.13205. http://www.ncbi.nlm.nih.gov/pubmed/28631393.
  • Loaiza-Betancur AF, Chulvi-Medrano I. Is Low-Intensity Isometric Handgrip Exercise an Efficient Alternative in Lifestyle Blood Pressure Management? A Systematic Review. Sports Health 2020; 12(5):470–7. DOI: 10.1177/1941738120943882. http://www.ncbi.nlm.nih.gov/pubmed/32776866.
  • Loboz KK, Shenfield GM. Drug combinations and impaired renal function - the 'triple whammy'. Br J Clin Pharmacol 2005; 59(2):239–43. DOI: 10.1111/j.0306-5251.2004.2188.x. http://www.ncbi.nlm.nih.gov/pubmed/15676048.
  • Ludwig W-D, Mühlbauer B, Seifert R. Arzneiverordnungs-Report 2021. Berlin, Heidelberg: Springer Berlin Heidelberg; 2021.
  • Luo Y, Ren L, Jiang M, et al. Anti-hypertensive efficacy of amlodipine dosing during morning versus evening: A meta-analysis. Rev Cardiovasc Med 2019; 20(2):91–8. DOI: 10.31083/j.rcm.2019.02.31814. http://www.ncbi.nlm.nih.gov/pubmed/31345001.
  • Ma C, Zhou Y, Zhou W, et al. Evaluation of the effect of motivational interviewing counselling on hypertension care. Patient Educ Couns 2014; 95(2):231–7. DOI: 10.1016/j.pec.2014.01.011. http://www.ncbi.nlm.nih.gov/pubmed/24530144.
  • Macdonald HV, Johnson BT, Huedo-Medina TB, et al. Dynamic Resistance Training as Stand-Alone Antihypertensive Lifestyle Therapy: A Meta-Analysis. J Am Heart Assoc 2016; 5(10). DOI: 10.1161/JAHA.116.003231. http://www.ncbi.nlm.nih.gov/pubmed/27680663.
  • Machnicki G, Ong SH, Chen W, et al. Comparison of amlodipine/valsartan/hydrochlorothiazide single pill combination and free combination: Adherence, persistence, healthcare utilization and costs. Curr Med Res Opin 2015; 31(12):2287–96. DOI: 10.1185/03007995.2015.1098598. http://www.ncbi.nlm.nih.gov/pubmed/26397178.
  • Mah GT, Tejani AM, Musini VM. Methyldopa for primary hypertension. Cochrane Database Syst Rev 2009(4):CD003893. DOI: 10.1002/14651858.CD003893.pub3. http://www.ncbi.nlm.nih.gov/pubmed/19821316.
  • Mahfoud F, Bakris G, Bhatt DL, et al. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: Data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. Eur Heart J 2017; 38(2):93–100. DOI: 10.1093/eurheartj/ehw325. http://www.ncbi.nlm.nih.gov/pubmed/28158510.
  • Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): A randomised, sham-controlled trial. Lancet 2022; 399(10333):1401–10. DOI: 10.1016/S0140-6736(22)00455-X. http://www.ncbi.nlm.nih.gov/pubmed/35390320.
  • Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: A meta-analysis. Lancet 2012; 380(9854):1649–61. DOI: 10.1016/S0140-6736(12)61272-0. http://www.ncbi.nlm.nih.gov/pubmed/23013600.
  • Mahn JJ, Dubey E, Brody A, et al. Test characteristics of electrocardiography for detection of left ventricular hypertrophy in asymptomatic emergency department patients with hypertension. Acad Emerg Med 2014; 21(9):996–1002. DOI: 10.1111/acem.12462. http://www.ncbi.nlm.nih.gov/pubmed/25269580.
  • Mathiassen ON, Vase H, Bech JN, et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. J Hypertens 2016; 34(8):1639–47. DOI: 10.1097/HJH.0000000000000977. http://www.ncbi.nlm.nih.gov/pubmed/27228432.
  • Matsushita K, Ballew SH, Astor BC, et al. Cohort profile: The chronic kidney disease prognosis consortium. Int J Epidemiol 2013; 42(6):1660–8. DOI: 10.1093/ije/dys173. http://www.ncbi.nlm.nih.gov/pubmed/23243116.
  • McGuinness B, Todd S, Passmore P, et al. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev 2009(4):CD004034. DOI: 10.1002/14651858.CD004034.pub3. http://www.ncbi.nlm.nih.gov/pubmed/19821318.
  • Mengden T, Weisser B. Monitoring of Treatment for Arterial Hypertension. Dtsch Arztebl Int 2021; 118(27-28):473–8. DOI: 10.3238/arztebl.m2021.0158. http://www.ncbi.nlm.nih.gov/pubmed/33734987.
  • Mori D, Kashihara Y, Yoshikado T, et al. Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. Drug Metab Pharmacokinet 2019; 34(1):78–86. DOI: 10.1016/j.dmpk.2018.09.003. http://www.ncbi.nlm.nih.gov/pubmed/30528195.
  • Musini VM, Lawrence KA, Fortin PM, et al. Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database Syst Rev 2017; 4(4):CD007066. DOI: 10.1002/14651858.CD007066.pub3. http://www.ncbi.nlm.nih.gov/pubmed/28379619.
  • Musini VM, Nazer M, Bassett K, et al. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev 2014(5):CD003824. DOI: 10.1002/14651858.CD003824.pub2. http://www.ncbi.nlm.nih.gov/pubmed/24869750.
  • Musini VM, Rezapour P, Wright JM, et al. Blood pressure-lowering efficacy of loop diuretics for primary hypertension. Cochrane Database Syst Rev 2015(5):CD003825. DOI: 10.1002/14651858.CD003825.pub4. http://www.ncbi.nlm.nih.gov/pubmed/26000442.
  • National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. 2019 (NICE Clinical Guideline; 136) [cited: 2020-01-14]. https://www.nice.org.uk/guidance/ng136/resources/hypertension-in-adults-diagnosis-and-management-pdf-66141722710213.
  • National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management [A] Evidence review for diagnosis. 2019 (NICE Clinical Guideline; 136) [cited: 2020-01-14]. https://www.nice.org.uk/guidance/ng136/evidence/a-diagnosis-pdf-6896748206.
  • National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management [B] Evidence review for monitoring. 2019 (NICE Clinical Guideline; 136) [cited: 2020-01-14]. https://www.nice.org.uk/guidance/ng136/evidence/b-monitoring-pdf-6896748207.
  • National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management [D] Evidence review for targets. 2019 (NICE Clinical Guideline; 136) [cited: 2020-01-14]. https://www.nice.org.uk/guidance/ng136/evidence/d-targets-pdf-6896748209.
  • National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management [H] Evidence review for relaxation therapies. 2019 (NICE Clinical Guideline; 136) [cited: 2020-01-14]. https://www.nice.org.uk/guidance/ng136/evidence/h-relaxation-therapies-pdf-6896748213.
  • National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management [G] Evidence review for step 4 treatment. 2019 (NICE Clinical Guideline; 136) [cited: 2020-01-14]. https://www.nice.org.uk/guidance/ng136/evidence/g-step-4-treatment-pdf-6896748212.
  • National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management [E] Evidence review for step 1 treatment. 2019 (NICE Clinical Guideline; 136) [cited: 2020-01-14]. https://www.nice.org.uk/guidance/ng136/evidence/e-step-1-treatment-pdf-6896748210.
  • National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management [C] Evidence review for initiating treatment. 2019 (NICE Clinical Guideline; 136) [cited: 2020-01-14]. https://www.nice.org.uk/guidance/ng136/evidence/c-initiating-treatment-pdf-6896748208.
  • National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management [F] Evidence review for step 2 and step 3 treatment. 2019 (NICE Clinical Guideline; 136) [cited: 2020-01-14]. https://www.nice.org.uk/guidance/ng136/evidence/f-step-2-and-step-3-treatment-pdf-6896748211.
  • National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: Evidence review for interventions for chronic hypertension. London; 2019 (NICE Guideline; 133). https://www.nice.org.uk/guidance/ng133/evidence/a-interventions-for-chronic-hypertension-pdf-6836186126.
  • National Institute for Health and Care Excellence (NICE). Implanting a baroreceptor stimulation device for resistant hypertension. 2015 (Interventional procedures guidance; 533) [cited: 2020-01-14]. https://www.nice.org.uk/guidance/ipg533/resources/implanting-a-baroreceptor-stimulation-device-for-resistant-hypertension-pdf-1899871864647109.
  • NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021; 398(10304):957–80. DOI: 10.2188/jea.JE20200089. http://www.ncbi.nlm.nih.gov/pubmed/34450083.
  • Neal B, Wu Y, Feng X, et al. Effect of Salt Substitution on Cardiovascular Events and Death. N Engl J Med 2021; 385(12):1067–77. DOI: 10.1056/NEJMoa2105675. http://www.ncbi.nlm.nih.gov/pubmed/34459569.
  • Neuhauser H, Kuhnert R, Born S. 12-Monats-Prävalenz von Bluthochdruck in Deutschland. J Health Monit 2017; 2(1):57–63. DOI: 10.17886/RKI-GBE-2017-007.
  • Neuhauser H, Thamm M, Ellert U. Blutdruck in Deutschland 2008-2011: Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56(5-6):795–801. DOI: 10.1007/s00103-013-1669-6. http://www.ncbi.nlm.nih.gov/pubmed/23703500.
  • Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2014(11):CD000011. DOI: 10.1002/14651858.CD000011.pub4. http://www.ncbi.nlm.nih.gov/pubmed/25412402.
  • Oliveira-Paula GH, Pereira SC, Tanus-Santos JE, et al. Pharmacogenomics And Hypertension: Current Insights. Pharmgenomics Pers Med 2019; 12:341–59. DOI: 10.2147/PGPM.S230201. http://www.ncbi.nlm.nih.gov/pubmed/31819590.
  • Palmer MJ, Barnard S, Perel P, et al. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults. Cochrane Database Syst Rev 2018; 6(6):CD012675. DOI: 10.1002/14651858.CD012675.pub2. http://www.ncbi.nlm.nih.gov/pubmed/29932455.
  • Palmer MJ, Machiyama K, Woodd S, et al. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults. Cochrane Database Syst Rev 2021; 3:CD012675. DOI: 10.1002/14651858.CD012675.pub3. http://www.ncbi.nlm.nih.gov/pubmed/33769555.
  • Pareek AK, Messerli FH, Chandurkar NB, et al. Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring. J Am Coll Cardiol 2016; 67(4):379–89. DOI: 10.1016/j.jacc.2015.10.083. http://www.ncbi.nlm.nih.gov/pubmed/26821625.
  • Parving H-H, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367(23):2204–13. DOI: 10.1056/NEJMoa1208799. http://www.ncbi.nlm.nih.gov/pubmed/23121378.
  • Perez MI, Musini VM. Pharmacological interventions for hypertensive emergencies. Cochrane Database Syst Rev 2008(1):CD003653. DOI: 10.1002/14651858.CD003653.pub3. http://www.ncbi.nlm.nih.gov/pubmed/18254026.
  • Peters CD, Mathiassen ON, Vase H, et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: A substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Press 2017; 26(6):366–80. DOI: 10.1080/08037051.2017.1368368. http://www.ncbi.nlm.nih.gov/pubmed/28830251.
  • Pisano A, Iannone LF, Leo A, et al. Renal denervation for resistant hypertension. Cochrane Database Syst Rev 2021; 11:CD011499. DOI: 10.1002/14651858.CD011499.pub3. http://www.ncbi.nlm.nih.gov/pubmed/34806762.
  • Posadzki P, Mastellos N, Ryan R, et al. Automated telephone communication systems for preventive healthcare and management of long-term conditions. Cochrane Database Syst Rev 2016; 12(12):CD009921. DOI: 10.1002/14651858.CD009921.pub2. http://www.ncbi.nlm.nih.gov/pubmed/27960229.
  • Prieto-García L, Pericacho M, Sancho-Martínez SM, et al. Mechanisms of triple whammy acute kidney injury. Pharmacol Ther 2016; 167:132–45. DOI: 10.1016/j.pharmthera.2016.07.011. http://www.ncbi.nlm.nih.gov/pubmed/27490717.
  • Rees K, Takeda A, Martin N, et al. Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2019; 3(3):CD009825. DOI: 10.1002/14651858.CD009825.pub3. http://www.ncbi.nlm.nih.gov/pubmed/30864165.
  • Reeve E, Jordan V, Thompson W, et al. Withdrawal of antihypertensive drugs in older people. Cochrane Database Syst Rev 2020; 6(6):CD012572. DOI: 10.1002/14651858.CD012572.pub2. http://www.ncbi.nlm.nih.gov/pubmed/32519776.
  • Rossi A, Dikareva A, Bacon SL, et al. The impact of physical activity on mortality in patients with high blood pressure: A systematic review. J Hypertens 2012; 30(7):1277–88. DOI: 10.1097/HJH.0b013e3283544669. http://www.ncbi.nlm.nih.gov/pubmed/22573122.
  • Roush GC, Ernst ME, Kostis JB, et al. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: Antihypertensive and metabolic effects. Hypertension 2015; 65(5):1041–6. DOI: 10.1161/HYPERTENSIONAHA.114.05021. http://www.ncbi.nlm.nih.gov/pubmed/25733245.
  • Rysz J, Franczyk B, Rysz-Górzyńska M, et al. Pharmacogenomics of Hypertension Treatment. Int J Mol Sci 2020; 21(13). DOI: 10.3390/ijms21134709. http://www.ncbi.nlm.nih.gov/pubmed/32630286.
  • Saiz LC, Gorricho J, Garjón J, et al. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. Cochrane Database Syst Rev 2020; 9:CD010315. DOI: 10.1002/14651858.CD010315.pub4. http://www.ncbi.nlm.nih.gov/pubmed/32905623.
  • Saseen JJ, Ghushchyan V, Nair KV. Comparing clinical effectiveness and drug toxicity with hydrochlorothiazide and chlorthalidone using two potency ratios in a managed care population. J Clin Hypertens (Greenwich) 2015; 17(2):134–40. DOI: 10.1111/jch.12453. http://www.ncbi.nlm.nih.gov/pubmed/25496048.
  • Schienkiewitz A, Mensink GBM, Kuhnert R. Übergewicht und Adipositas bei Erwachsenen in Deutschland. J Health Monit 2017; 2(2):21–8. DOI: 10.17886/RKI-GBE-2017-025.
  • Schmieder RE, Ott C, Toennes SW, et al. Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension - WAVE IV. J Hypertens 2018; 36(3):680–9. DOI: 10.1097/HJH.0000000000001584. http://www.ncbi.nlm.nih.gov/pubmed/29035942.
  • Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 2004(2):CD004804. http://www.ncbi.nlm.nih.gov/pubmed/15106262.
  • Schulz M, Krueger K, Schuessel K, et al. Medication adherence and persistence according to different antihypertensive drug classes: A retrospective cohort study of 255,500 patients. Int J Cardiol 2016; 220:668–76. DOI: 10.1016/j.ijcard.2016.06.263. http://www.ncbi.nlm.nih.gov/pubmed/27393848.
  • Semlitsch T, Jeitler K, Berghold A, et al. Long-term effects of weight-reducing diets in people with hypertension. Cochrane Database Syst Rev 2016; 3(3):CD008274. DOI: 10.1002/14651858.CD008274.pub3. http://www.ncbi.nlm.nih.gov/pubmed/26934541.
  • Semlitsch T, Krenn C, Jeitler K, et al. Long-term effects of weight-reducing diets in people with hypertension. Cochrane Database Syst Rev 2021; 2(2):CD008274. DOI: 10.1002/14651858.CD008274.pub4. http://www.ncbi.nlm.nih.gov/pubmed/33555049.
  • Shamon SD, Perez MI. Blood pressure-lowering efficacy of reserpine for primary hypertension. Cochrane Database Syst Rev 2016; 12(12):CD007655. DOI: 10.1002/14651858.CD007655.pub3. http://www.ncbi.nlm.nih.gov/pubmed/27997978.
  • Shao Q, Meng L, Tse G, et al. Newly proposed electrocardiographic criteria for the diagnosis of left ventricular hypertrophy in a Chinese population. Ann Noninvasive Electrocardiol 2019; 24(2):e12602. DOI: 10.1111/anec.12602. http://www.ncbi.nlm.nih.gov/pubmed/30281188.
  • Si S, Ofori-Asenso R, Briffa T, et al. Long-term persistence and adherence to blood pressure lowering agents among older Australians. Pharmacoepidemiol Drug Saf 2019; 28(6):788–95. DOI: 10.1002/pds.4742. http://www.ncbi.nlm.nih.gov/pubmed/30784140.
  • Smith SM, Cousins G, Clyne B, et al. Shared care across the interface between primary and specialty care in management of long term conditions. Cochrane Database Syst Rev 2017; 2(2):CD004910. DOI: 10.1002/14651858.CD004910.pub3. http://www.ncbi.nlm.nih.gov/pubmed/28230899.
  • Smith SM, Wallace E, O'Dowd T, et al. Interventions for improving outcomes in patients with multimorbidity in primary care and community settings. Cochrane Database Syst Rev 2021; 1(1):CD006560. DOI: 10.1002/14651858.CD006560.pub4. http://www.ncbi.nlm.nih.gov/pubmed/33448337.
  • Stacey D, Légaré F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2017; 4(4):CD001431. DOI: 10.1002/14651858.CD001431.pub5. http://www.ncbi.nlm.nih.gov/pubmed/28402085.
  • Steed L, Sohanpal R, Todd A, et al. Community pharmacy interventions for health promotion: Effects on professional practice and health outcomes. Cochrane Database Syst Rev 2019; 12(12):CD011207. DOI: 10.1002/14651858.CD011207.pub2. http://www.ncbi.nlm.nih.gov/pubmed/31808563.
  • Strohm D, Boeing H, Leschik-Bonnet E, et al. Speisesalzzufuhr in Deutschland, gesundheitliche Folgen und resultierende Handlungsempfehlung. Ernahrungs Umschau 2016; 63(3):62–70. DOI: 10.4455/eu.2016.012.
  • Sun Y, Yu X, Liu J, et al. Effect of bedtime administration of blood-pressure lowering agents on ambulatory blood pressure monitoring results: A meta-analysis. Cardiol J 2016; 23(4):473–81. DOI: 10.5603/CJ.a2016.0027. http://www.ncbi.nlm.nih.gov/pubmed/27296158.
  • Tam TS, Wu MH, Masson SC, et al. Eplerenone for hypertension. Cochrane Database Syst Rev 2017; 2(2):CD008996. DOI: 10.1002/14651858.CD008996.pub2. http://www.ncbi.nlm.nih.gov/pubmed/28245343.
  • Tasnim S, Tang C, Musini VM, et al. Effect of alcohol on blood pressure. Cochrane Database Syst Rev 2020(7):CD012787. DOI: 10.1002/14651858.CD012787.pub2. http://www.ncbi.nlm.nih.gov/pubmed/32609894.
  • Tita AT, Szychowski JM, Boggess K, et al. Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med 2022; 386(19):1781–92. DOI: 10.1056/NEJMoa2201295. http://www.ncbi.nlm.nih.gov/pubmed/35363951.
  • Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): A randomised, sham-controlled, proof-of-concept trial. Lancet 2017; 390(10108):2160–70. DOI: 10.1016/S0140-6736(17)32281-X. http://www.ncbi.nlm.nih.gov/pubmed/28859944.
  • van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011; 79(12):1341–52. DOI: 10.1038/ki.2010.536. http://www.ncbi.nlm.nih.gov/pubmed/21307840.
  • Verma AA, Khuu W, Tadrous M, et al. Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study. PLoS Med 2018; 15(6):e1002584. DOI: 10.1371/journal.pmed.1002584. http://www.ncbi.nlm.nih.gov/pubmed/29889841.
  • Visseren FL, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42(34):3227–337. DOI: 10.1093/eurheartj/ehab484. http://www.ncbi.nlm.nih.gov/pubmed/34458905.
  • Wang GM, Li LJ, Tang WL, et al. Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev 2020; 10(10):CD012569. DOI: 10.1002/14651858.CD012569.pub2. http://www.ncbi.nlm.nih.gov/pubmed/33089502.
  • Webb DJ, Muirhead GJ, Wulff M, et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 2000; 36(1):25–31. DOI: 10.1016/s0735-1097(00)00705-1. http://www.ncbi.nlm.nih.gov/pubmed/10898408.
  • Weber MA, Kirtane AJ, Weir MR, et al. The REDUCE HTN: REINFORCE: Randomized, Sham-Controlled Trial of Bipolar Radiofrequency Renal Denervation for the Treatment of Hypertension. JACC Cardiovasc Interv 2020; 13(4):461–70. DOI: 10.1016/j.jcin.2019.10.061. http://www.ncbi.nlm.nih.gov/pubmed/32081240.
  • Weeks G, George J, Maclure K, et al. Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care. Cochrane Database Syst Rev 2016; 11(11):CD011227. DOI: 10.1002/14651858.CD011227.pub2. http://www.ncbi.nlm.nih.gov/pubmed/27873322.
  • Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71(6):1269–324. DOI: 10.1161/HYP.0000000000000066. http://www.ncbi.nlm.nih.gov/pubmed/29133354.
  • Wilke T, Weisser B, Predel H-G, et al. Effects of Single Pill Combinations Compared to Identical Multi Pill Therapy on Outcomes in Hypertension, Dyslipidemia and Secondary Cardiovascular Prevention: The START-Study. Integr Blood Press Control 2022; 15:11–21. DOI: 10.2147/IBPC.S336324. http://www.ncbi.nlm.nih.gov/pubmed/35250308.
  • Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33):3021–104. DOI: 10.1093/eurheartj/ehy339. http://www.ncbi.nlm.nih.gov/pubmed/30165516.
  • Wissenschaftliches Institut der AOK (WIdO), Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen. Amtliche Fassung des ATC-Index mit DDD-Angaben für Deutschland im Jahr 2021. 2021 [cited: 2021-06-16]. https://www.dimdi.de/dynamic/.downloads/arzneimittel/atcddd/atc-ddd-amtlich-2021.pdf.
  • Wiysonge CS, Bradley HA, Volmink J, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2017; 1:CD002003. DOI: 10.1002/14651858.CD002003.pub5. http://www.ncbi.nlm.nih.gov/pubmed/28107561.
  • Wong GW, Boyda HN, Wright JM. Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension. Cochrane Database Syst Rev 2016; 3(3):CD007451. DOI: 10.1002/14651858.CD007451.pub2. http://www.ncbi.nlm.nih.gov/pubmed/26961574.
  • Wong GW, Laugerotte A, Wright JM. Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension. Cochrane Database Syst Rev 2015(8):CD007449. DOI: 10.1002/14651858.CD007449.pub2. http://www.ncbi.nlm.nih.gov/pubmed/26306578.
  • Wong GW, Wright JM. Blood pressure lowering efficacy of nonselective beta-blockers for primary hypertension. Cochrane Database Syst Rev 2014(2):CD007452. DOI: 10.1002/14651858.CD007452.pub2. http://www.ncbi.nlm.nih.gov/pubmed/24585007.
  • Wright JM, Musini VM, Gill R. First-line drugs for hypertension. Cochrane Database Syst Rev 2018; 4(4):CD001841. DOI: 10.1002/14651858.CD001841.pub3. http://www.ncbi.nlm.nih.gov/pubmed/29667175.
  • Xie Z, Zhang J, Wang C, et al. Chronotherapy for morning blood pressure surge in hypertensive patients: A systematic review and meta-analysis. BMC Cardiovasc Disord 2021; 21(1):274. DOI: 10.1186/s12872-021-02081-8. http://www.ncbi.nlm.nih.gov/pubmed/34088274.
  • Zeiher J, Kuntz B, Lange C. Rauchen bei Erwachsenen in Deutschland. J Health Monit 2017; 2(2):59–65. DOI: 10.17886/RKI-GBE-2017-030.
  • Zhang X-Y, Soufi S, Dormuth C, et al. Time course for blood pressure lowering of beta-blockers with partial agonist activity. Cochrane Database Syst Rev 2020; 9(9):CD010054. DOI: 10.1002/14651858.CD010054.pub2. http://www.ncbi.nlm.nih.gov/pubmed/32888198.
  • Zhao P, Xu P, Wan C, et al. Evening versus morning dosing regimen drug therapy for hypertension. Cochrane Database Syst Rev 2011(10):CD004184. DOI: 10.1002/14651858.CD004184.pub2. http://www.ncbi.nlm.nih.gov/pubmed/21975743.
  • Zhu J, Chen N, Zhou M, et al. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database Syst Rev 2022; 1(1):CD003654. DOI: 10.1002/14651858.CD003654.pub6. http://www.ncbi.nlm.nih.gov/pubmed/35000192.
  • Zipkin DA, Umscheid CA, Keating NL, et al. Evidence-based risk communication: A systematic review. Ann Intern Med 2014; 161(4):270–80. DOI: 10.7326/M14-0295. http://www.ncbi.nlm.nih.gov/pubmed/25133362.

 
NVL Hypertonie, Version 1.0, 2023

NVL Hypertonie – Weitere Formate

Bitte beachten Sie, dass nur die unter www.leitlinien.de enthaltenen Dokumente des Programms für Nationale VersorgungsLeitlinien durch die Träger des NVL-Programms autorisiert und damit gültig sind. Bei NVL-Dokumenten, die Sie von anderen Webseiten beziehen, übernehmen wir keine Verantwortung für deren Gültigkeit.

Das Archiv enthält abgelaufene, zurückgezogene Dokumente zur Nationalen Versorgungsleitlinie Hypertonie.

Hinweise und Kommentare

Sie haben Hinweise und Kommentare zu unserem Internetangebot?

zuletzt verändert: 29.06.2023 | 10:08 Uhr
Inhalt